Alnylam Pharmaceuticals (ALNY) Interest Expenses (2020 - 2026)

Alnylam Pharmaceuticals (ALNY) has 7 years of Interest Expenses data on file, last reported at $69.3 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 18.83% year-over-year to $69.3 million; the trailing twelve-month figure through Mar 2026 stood at $219.3 million (up 33.0% YoY), and the FY2025 full-year result was $252.6 million, up 78.08% from the prior year.
• Interest Expenses for Q1 2026 stood at $69.3 million, up from $65.4 million in the prior quarter.
• Across five years, Interest Expenses topped out at $69.3 million in Q1 2026 and bottomed at $29.0 million in Q1 2023.
• The 5-year median for Interest Expenses is $39.0 million (2024), against an average of $41.0 million.
• The widest annual swing landed in 2023, when Interest Expenses sank 31.65%; it then soared 67.82% in 2025.
• A 5-year view of Interest Expenses shows it stood at $29.9 million in 2022, then increased by 4.76% to $31.3 million in 2023, then climbed by 24.36% to $39.0 million in 2024, then soared by 67.82% to $65.4 million in 2025, then climbed by 5.94% to $69.3 million in 2026.
• The last three Interest Expenses figures came in at $69.3 million (Q1 2026), $65.4 million (Q4 2025), and $44.4 million (Q3 2025), per Business Quant data.

Peer Comparison